Navigation Links
EU Study Finds UK Health Product Benefit Metric Flawed
Date:2/1/2013

Washington, D.C. (PRWEB) January 31, 2013

RegLink News, in its monitoring of developments at regulatory and health technology assessment (HTA) agencies around the world, is accustomed to reporting on decisions as to coverage or not of new drugs and medical devices. This week’s HTA news has significance well beyond a particular product: A study funded by the European Commission has just concluded that the formula used by the UK’s healthcare cost containment watchdog, the National Institute for Health and Clinical Excellence (NICE), doesn’t work – and in so doing has sparked off a debate on the subject of determining patient access to new therapies.

The study, conducted by the European Consortium on Healthcare Outcomes and Cost-Benefit research (ECHOUTCOME), examined the scientific validity NICE’s formula – Quality Adjusted Life Years (QALY) – and found that it doesn’t reflect real world needs and preferences of patients.

QALY weighs the number of life years and the improvement to quality of life, and is the basis for reimbursement decisions delivered by many health technology assessment (HTA) agencies around the world, including – in addition to NICE – those in Canada and Australia. The metric has, however, been rejected by some HTA bodies, including notably Germany’s IQWiG.

The ECHOUTCOME group’s report on NICE’s methodology comes right out and says that the use of QALY “produce[s] hugely inconsistent, wrong results, on which important [reimbursement] decisions are based.” The report concludes that all four of the assumptions which allegedly support the use of QALY are invalid: (1) that time and quality of life can be measured in consistent intervals; (2) that life years and quality of life are linked; (3) that people are neutral about risk; and (4) that willingness to sacrifice life years is co
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Positive Clinical Study Results for BSPs HyperQ Technology
2. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
3. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
4. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver
5. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. Singapore scientists lead human embryonic stem cell study
9. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
10. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
11. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 Spirax Sarco, the leader ... their newly designed, state-of-the-art website in the first ... effectively promotes the Spirax Sarco brand, company capabilities, ... that a site visitor might be looking for ... industries serviced, the latest company news, careers, and ...
(Date:4/16/2015)... CA (PRWEB) April 16, 2015 Cytokinetics, ... to report first quarter results on Thursday, April 30, ... Cytokinetics’ senior management will host a conference call at ... results and the company’s outlook for the future. , ... be accessed from the homepage and in the Investor ...
(Date:4/16/2015)... , April 16, 2015  Schulman Associates IRB, Inc., ... has signed a long-term lease on Laboratory Drive in ... Carolina . The location will house review board ... provide high quality reviews and customer service to clients. ... represented Schulman in the deal, while Capital Associates ...
(Date:4/16/2015)... CHARLOTTE, N.C. (PRWEB) April 16, 2015 ... North Carolina at Charlotte (UNC Charlotte) spin-out company, ... David L. Cooper, Ph.D., M.D., as Chief Operating ... 20 years of experience in developing clinical diagnostic ... oncology and infectious disease. , Cooper’s extensive career ...
Breaking Biology Technology:Spirax Sarco website has a new look 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2OncoTAb Names Dr. David L. Cooper as COO 2
... Inc. (Nasdaq: VVUS ), a biopharmaceutical company ... today reported its highlights and financial results for the third ... Quarter Highlights , In the third quarter of ... pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the ...
... Nov. 3 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) ... provide an update on the progress of Sangamo,s ZFP Therapeutic(TM) ... at 2:20 pm ET on Tuesday, November 10, 2009 at ... be held in New York City. , The presentation will ...
... WILMINGTON, Delaware, November 3 The ... Technologies Market, (2009 - 2014),published by MarketsandMarkets ( ... stem cell market. It identifies and analyzes,the main ... services, technologies, and applications submarkets in different,geographic regions. ...
Cached Biology Technology:VIVUS Reports Third Quarter 2009 Highlights and Financial Results 2VIVUS Reports Third Quarter 2009 Highlights and Financial Results 3VIVUS Reports Third Quarter 2009 Highlights and Financial Results 4VIVUS Reports Third Quarter 2009 Highlights and Financial Results 5VIVUS Reports Third Quarter 2009 Highlights and Financial Results 6VIVUS Reports Third Quarter 2009 Highlights and Financial Results 7VIVUS Reports Third Quarter 2009 Highlights and Financial Results 8Sangamo BioSciences Announces Presentation at Merriman Curhan Ford's Investor Summit 2009 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 3
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... the dead bone of a transplanted skeletal graft into living ... gene therapy to stimulate the body into treating the foreign ... thousands of cancer and trauma patients each year who suffer ... online Feb. 13 and will appear in the March 1 ...
... Malignancies Program at the H. Lee Moffitt Cancer Center ... of the experimental drug Revlimid showing promise as an ... a form of pre-leukemia. Given in pill form, Revlimid ... nourish tumors (anti-angiogenesis) and stimulates the immune system to ...
... many years, DNA and proteins have been,viewed as ... with RNA seen,as little more than a messenger ... Whitehead Institute for Biomedical Research,and Massachusetts Institute of ... regulate thousands of human genes--more,than one third of ...
Cached Biology News:Gene therapy converts dead bone graft to new, living tissue 2Gene therapy converts dead bone graft to new, living tissue 3Gene therapy converts dead bone graft to new, living tissue 4Leukemia Drug Breakthrough Study In New England Journal Of Medicine 2NYU researchers simulate molecular biological clock 2
... 1-D PAGE Cleavable ICAT ... Targeted Protein ID and ... Gel Electrophoresis (PAGE), isotope-coded ... cleavable-linker technology to facilitate ...
Supplemental reagent for annexin V assay....
Antibody Purification Specificity: Antibody Purification ...
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
Biology Products: